Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: September 2008
-
By Kevin E. Noonan — Harold Wegner, dean of patent law cognoscenti and a partner at Foley & Lardner LLP in Washington, DC, regaled the audience at ACI’s Biotech Patent Law conference on Monday with a talk on "Key Biotech Cases to Watch and How They May Impact Your Practice." Ranging from §…
-
By Donald Zuhn — Last week, Allele Biotechnology & Pharmaceuticals, Inc. announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,422,896, which is directed to DNA compositions that mediate RNA interference (RNAi) gene silencing, wherein the DNA compositions include an RNA polymerase III promoter that drives the expression of…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. University of Iowa et al. v. Amgen, Inc. et al.3:08-cv-00112; filed September 8, 2008 in the Southern District of Iowa Infringement of…
-
September 15-16, 2008 – Biotech Patents*** (American Conference Institute) September 16, 2008 – The Legacy of Judge Howard T. Markey*** (The Center for Intellectual Property Law, John Marshall Law School) – Chicago, IL September 21-23, 2008 – 2008 Annual Meeting (Intellectual Property Owners Association) – San Diego, CA September 22-23, 2008 – FDA Boot Camp***…
-
By Donald Zuhn — Last month, we reported on the lobbying expenditures for fourteen biotech and pharma companies and organizations in the second quarter of 2008. Recent news reports have allowed us to add four more companies to the list: • Sanofi-Aventis’ U.S. subsidiary spent more than $1.2 million on second quarter lobbying…
-
By Donald Zuhn — On June 10, 2008, the U.S. Patent and Trademark Office published a notice in the Federal Register setting forth amended rules of practice before the Board of Patent Appeals and Interferences (BPAI) in ex parte appeals (see "New Appeals Rules Published"). What escaped the attention of the patent community…
-
By Kevin E. Noonan — Over the past year, the Federal Circuit has addressed on many occasions the scope of the "case or controversy" requirement for a court to have jurisdiction under Article III of the Constitution. Several of these decisions have been directed to the proper jurisdictional scope of declaratory judgment actions…
-
By Donald Zuhn — On Monday, the Federal Circuit affirmed a finding on summary judgment by the District Court for the Northern District of California that the asserted claims of U.S. Patent Nos. 4,767,708 and 5,126,270 and certain asserted claims of U.S. Patent No. 6,017,745 are invalid, and that the remainder of the…
-
By Kevin E. Noonan — Re-examination, whether ex parte under 35 U.S.C. § 302-307 or inter partes under 35 U.S.C. § 311-318, is a procedure intended to provide an alternative to patent litigation, which Congress characterized as being expensive and inefficient in passing legislation establishing these two routes of post-grant challenge (see H.R.…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Glaxo Group Ltd. et al. v. Lupin Ltd. et al.1:08-cv-00551; filed August 29, 2008 in the District Court of Delaware Infringement of…
Patent Docs 